FDA Approves Broadly Inclusive Phase IIa ALS Clinical Trial with GM604, a Biotechnology Innovation

Offering imminent hope for those with ALS, Genervon Biopharmaceuticals, an innovative biotechnology company announced today that it has received FDA approval and is now recruiting patients for its broadly inclusive ALS clinical trial.

http://www.businesswire.com/news/home/20130528005381/en/FDA-Approves-Broadly-Inclusive-Phase-IIa-ALS